Steven Yatomi-Clarke – CEO & Managing Director – Prescient Therapeutics is focused on developing novel, personalised therapies for a range of cancers.

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast….

The appointment gives PTX a world-leading development team in the race to find solutions for next-generation CAR-T cancer therapies. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has…

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to its scientific advisory board. Professor O’Rourke has considerable expertise in…

Researchers at the University of Pennsylvania (Penn) are developing a new way for cancer-fighting CAR-T cells to overcome the resistance present in some types of…

Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s innovative pipeline of personalised cancer therapies….

CAR-T therapies have proven to be revolutionary treatments for cancer, but their high costs have limited patient access. The Australian Federal Government have addressed this…

Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news. Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company…

Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple cancer programs, with work to follow on from…